"The approach is often to identify what treatments the patients have tried already, so we don't try those again, and then have a discussion about the pros and cons," says J. Quentin Clemens, MD, MSCI.

APPs can significantly alleviate workforce shortages in urology by handling routine clinical tasks, allowing urologists to focus on complex cases. Successful integration of APPs requires changing ...

According to Sanda, future advancements may involve gene and RNA sequencing, the use of AI in imaging, and multidisciplinary collaboration. In this video, Martin G. Sanda, MD, highlights key areas of ...

"There is new technology emerging for skin stimulation of the perineum that is just recently evolving to help control OAB symptoms," says Anne Pelletier Cameron, MD, FRCSC, FPMRS. In this video, Anne ...

The combination of belzutifan and cabozantinib showed promising antitumor activity in treatment-naïve ccRCC patients, with a 70% objective response rate and 98% disease control rate. Median duration ...

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life ...

Plasmacytoid urothelial carcinoma is rare and aggressive, with poor outcomes and challenges in accurate staging. National and institutional data reveal discrepancies in chemotherapy use and disease ...

"The notion that the urine is sterile should be hopefully abolished by now, especially in this group where we know that these individuals do have a lot of bacteria growing in their bladders," says ...

"We are trying to develop epigenetic biomarkers that can predict patients that are starting to progress to neuroendocrine prostate cancer," says Jindan Yu, MD, PhD. In this video, Jindan Yu, MD, PhD, ...

Illuccix is approved in Europe for PSMA-positive lesion detection in prostate cancer, following prior approvals in the US, Australia, and Canada. The phase 3 VISION trial showed 177Lu-PSMA-617 plus ...

CMS has selected 15 additional drugs for Medicare Part D price negotiations, aiming to lower healthcare costs for enrollees. The Inflation Reduction Act allows Medicare to negotiate drug prices, with ...

"My biggest hope for people reading this review is to understand that there are some golden opportunities for research," says Laura Bukavina, MD, MPH, MSc. Isali: I think our review mainly highlighted ...